Blackstone's $2B ZO Skin Health Opportunity

Blackstone (BX.N) has launched an early-stage sale process for medical-grade skincare brand ZO Skin Health, with sources pegging a potential deal value at roughly $2 billion, underscoring sustained private-equity appetite for clinically backed beauty assets.1

A successful exit would hand Blackstone a significant return on its investment in a niche skincare segment that commands premium pricing and physician-gated distribution - characteristics that have drawn strategic acquirers away from mass-market alternatives.

Key Takeaways

• Blackstone exploring ZO Skin Health sale at ~$2 billion valuation.
• Citigroup and Raymond James are advising on the process.
• Strategic buyers favor physician-distributed brands for steadier demand.

Deal Structure & Advisers

Blackstone has engaged Citigroup (C.N) and Raymond James (RJF.N) to run the sale, according to people familiar with the matter who requested anonymity because the discussions are private.1 The process is described as early-stage, meaning a timeline for binding bids has not been set.

No formal valuation has been disclosed by any party. The $2 billion figure cited by sources would position ZO Skin Health among the more richly valued independent medical-skincare brands in recent M&A history, reflecting a multiple consistent with high-growth, defensible consumer health businesses.

Market Context & Sector Positioning

The physician-dispensed skincare market has drawn elevated deal interest as strategic buyers - ranging from large dermatology groups to diversified beauty conglomerates - seek assets with clinical validation and distribution moats. ZO Skin Health competes in a segment that includes brands such as SkinMedica (owned by AbbVie) and Revision Skincare, both of which have also attracted premium valuations in prior transactions.

The broader medical-aesthetic space has remained active even as consumer-discretionary spending softened in 2025-2026, with physician-backed products proving more resilient than over-the-counter alternatives, sources familiar with buyer sentiment said.1

About ZO Skin Health

Dermatologist Dr. Zein Obagi founded ZO Skin Health in 2007. The brand markets a range of products - including cleansers, serums, exfoliators, and toners - distributed exclusively through physicians and licensed skincare professionals, a channel that limits price competition and supports brand integrity.

That physician-only distribution model is central to the bull case for prospective buyers. As one person familiar with deal rationale said, strategic acquirers are

"prioritizing clinically backed, physician-distributed skincare brands like ZO, because of their efficacy and steadier demand versus over-the-counter products."1

Implications for BX Investors

For shareholders of Blackstone (BX.N), a $2 billion exit from ZO Skin Health would represent a meaningful portfolio monetization, adding to the firm's realization pipeline at a time when IPO markets remain selective. Blackstone and Citigroup declined to comment; ZO Skin Health and Raymond James did not respond to requests for comment.1

The outcome of this process will be watched closely as a benchmark for how the market prices physician-channel skincare assets heading into 2027, with several comparable brands understood to be weighing strategic options of their own.

Conclusion

Blackstone's move to test the market for ZO Skin Health at a ~$2 billion valuation highlights the continued premium commanded by clinically differentiated, professionally distributed skincare assets. With Citigroup and Raymond James running the books, formal buyer outreach is likely to begin in the coming weeks, though the process remains at an early stage and no deal is certain.

Not investment advice. For informational purposes only.